title: Rosiglitazone REMS arrives in November.
authors.forename: Kate
authors.initials: K
authors.lastname: Traynor
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D047495:PPAR gamma / Q000819:agonists*; D010594:Pharmacies / Q000331:legislation & jurisprudence / Q000639:trends; D018570:Risk Assessment; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D014481:United States; D014665:Vasodilator Agents / Q000009:adverse effects*
chemical_list: D047495:PPAR gamma; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077154:Rosiglitazone